Cyclo Therapeutics Future Growth
Future criteria checks 2/6
Cyclo Therapeutics is forecast to grow earnings and revenue by 45.9% and 75.3% per annum respectively while EPS is expected to grow by 56% per annum.
Key information
45.9%
Earnings growth rate
56.0%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 75.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 27 Aug 2024 |
Recent future growth updates
Recent updates
Cyclo Therapeutics GAAP EPS of -$0.41 beats by $0.12, revenue of $0.54M misses by $0.08M
Aug 16Here's Why We're A Bit Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Situation
Jul 12
We're A Little Worried About Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate
Jan 20Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease
Nov 16Will Cyclo Therapeutics (NASDAQ:CYTH) Spend Its Cash Wisely?
Sep 28Cyclo therapeutics to join Russell 2000 Index
Jun 14We're Keeping An Eye On Cyclo Therapeutics' (NASDAQ:CYTH) Cash Burn Rate
Jun 12Cyclo Therapeutics posts design protocol of pivotal late-stage study of Trappsol Cyclo
Apr 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 15 | -22 | N/A | N/A | 2 |
| 12/31/2025 | 1 | -27 | N/A | -24 | 3 |
| 12/31/2024 | 1 | -22 | N/A | -22 | 3 |
| 9/30/2024 | 1 | -25 | -23 | -23 | N/A |
| 6/30/2024 | 1 | -21 | -18 | -18 | N/A |
| 3/31/2024 | 1 | -19 | -18 | -18 | N/A |
| 12/31/2023 | 1 | -20 | -16 | -16 | N/A |
| 9/30/2023 | 1 | -19 | -15 | -15 | N/A |
| 6/30/2023 | 1 | -19 | -14 | -14 | N/A |
| 3/31/2023 | 1 | -18 | -15 | -15 | N/A |
| 12/31/2022 | 1 | -15 | -15 | -15 | N/A |
| 9/30/2022 | 2 | -13 | -15 | -15 | N/A |
| 6/30/2022 | 2 | -13 | -15 | -15 | N/A |
| 3/31/2022 | 1 | -13 | -15 | -15 | N/A |
| 12/31/2021 | 2 | -14 | -15 | -15 | N/A |
| 9/30/2021 | 1 | -14 | -15 | -15 | N/A |
| 6/30/2021 | 1 | -12 | -14 | -14 | N/A |
| 3/31/2021 | 1 | -10 | -12 | -12 | N/A |
| 12/31/2020 | 1 | -9 | -9 | -9 | N/A |
| 9/30/2020 | 1 | -9 | -8 | -8 | N/A |
| 6/30/2020 | 1 | -9 | -8 | -8 | N/A |
| 3/31/2020 | 1 | -8 | -7 | -7 | N/A |
| 12/31/2019 | 1 | -8 | -7 | -7 | N/A |
| 9/30/2019 | 1 | -6 | -5 | -5 | N/A |
| 6/30/2019 | 1 | -5 | -4 | -4 | N/A |
| 3/31/2019 | 1 | -5 | -4 | -4 | N/A |
| 12/31/2018 | 1 | -4 | -3 | -3 | N/A |
| 9/30/2018 | 1 | -4 | -3 | -3 | N/A |
| 6/30/2018 | 1 | -4 | N/A | -3 | N/A |
| 3/31/2018 | 1 | -4 | N/A | -3 | N/A |
| 12/31/2017 | 1 | -4 | N/A | -3 | N/A |
| 9/30/2017 | 2 | -3 | N/A | -3 | N/A |
| 6/30/2017 | 2 | -4 | N/A | -3 | N/A |
| 3/31/2017 | 1 | -5 | N/A | -3 | N/A |
| 12/31/2016 | 2 | -4 | N/A | -3 | N/A |
| 9/30/2016 | 1 | -4 | N/A | -3 | N/A |
| 6/30/2016 | 1 | -4 | N/A | -3 | N/A |
| 3/31/2016 | 1 | -3 | N/A | -2 | N/A |
| 12/31/2015 | 1 | -3 | N/A | -2 | N/A |
| 9/30/2015 | 1 | -2 | N/A | -1 | N/A |
| 6/30/2015 | 1 | -1 | N/A | -1 | N/A |
| 3/31/2015 | 1 | -1 | N/A | -1 | N/A |
| 12/31/2014 | 2 | -1 | N/A | -1 | N/A |
| 9/30/2014 | 1 | 0 | N/A | 0 | N/A |
| 6/30/2014 | 1 | 0 | N/A | 0 | N/A |
| 3/31/2014 | 2 | 0 | N/A | 1 | N/A |
| 12/31/2013 | 2 | 0 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CYTH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CYTH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CYTH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CYTH's revenue (75.3% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: CYTH's revenue (75.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CYTH's Return on Equity is forecast to be high in 3 years time